Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

609
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
609
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

433
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
433
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

237
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
237
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

317
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
317
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

307
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
307
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

242
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
242

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Metastatic Malignant Melanoma Masquerading as Tolosa-Hunt Syndrome.

Case reports in ophthalmological medicine·2026
Same author

Redefining Obstructive Sleep Apnea: Treatment in the Modern Era.

Pathophysiology : the official journal of the International Society for Pathophysiology·2026
Same author

Cytomegalovirus Lymphadenitis Mimicking Relapsed Lymphoma After CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026
Same author

From Spider Bite to Fungating Ulcerating Mass: An Aggressive Squamous Cell Carcinoma of the Face.

Cureus·2025
Same author

Fragmented Chemotherapy of Plasmablastic Lymphoma in an Immunocompromised Patient.

Cureus·2025
Same author

Post-Hospitalization Home Monitoring Programs During the COVID-19 Pandemic: Survey Results from the Hospital Medicine Re-engineering Network (HOMERuN).

Journal of general internal medicine·2023

関連する実験動画

Updated: Jan 29, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.8K

亜ネフローゼ性タンパク尿下での血栓症

Jose Redondo1, Alexander J Dobek1, Leonardo B Sosa1

  • 1Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, USA.

Cureus
|January 28, 2026
PubMed
まとめ
この要約は機械生成です。

亜ネフローゼ性タンパク尿と低アルブミン血症の患者は、ネフローゼ症候群と同様に、血栓症のリスクが高い可能性がある。これは、これらの個人における静脈血栓塞栓症（VTE）の慎重な管理の必要性を強調するものである。

キーワード:
AAアミロイドーシス低アルブミン血症手技周りの抗凝固療法亜ネフローゼ性タンパク尿静脈血栓塞栓症（VTE）

さらに関連する動画

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.2K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.1K

関連する実験動画

Last Updated: Jan 29, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.8K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.2K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.1K

科学分野:

  • 腎臓病学
  • 血液学
  • 内科学

背景:

  • ネフローゼ症候群は、静脈血栓塞栓症（VTE）の既知のリスク因子である。
  • 亜ネフローゼ性タンパク尿および低アルブミン血症も、高凝固状態に寄与することがますます認識されている。
  • これらの病状における血栓症リスクの理解は、患者管理にとって極めて重要である。

研究 の 目的:

  • 亜ネフローゼ性タンパク尿、低アルブミン血症、およびVTEリスクの上昇との関連性を強調すること。
  • 抗凝固療法を一時的に中断した場合でもVTEが発生する可能性を示す症例を提示すること。
  • 腎疾患患者におけるVTEリスク管理のための包括的なアプローチの必要性を強調すること。

主な方法:

  • アナサルカ、呼吸困難、深部静脈血栓症（DVT）を呈した40歳患者の症例報告。
  • 腎生検前の抗凝固療法のー時的な中止中に発生したVTEの臨床観察。
  • 患者の臨床像および診断所見のレビュー。

主要な成果:

  • 患者は両下肢の深部静脈血栓症（DVT）と肺塞栓症を呈した。
  • 抗凝固療法を短期間中止すると、両上肢に新たなDVTが発症した。
  • 亜ネフローゼ性タンパク尿の文脈における低アルブミン血症は、血栓症リスクの潜在的な指標として注目された。

結論:

  • 亜ネフローゼ性タンパク尿および低アルブミン血症は、VTEの重要なリスク因子として考慮するに値する。
  • これらの病状を有する患者、特に手技により一時的な抗凝固療法の中止が必要な場合には、慎重な管理戦略が不可欠である。
  • この患者集団におけるVTE予防および治療の最適化のために、多職種アプローチが推奨される。